Literature DB >> 20510802

Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?

Antoine Brouquet1, Melinda M Mortenson, Jean-Nicolas Vauthey, Miguel A Rodriguez-Bigas, Michael J Overman, George J Chang, Scott Kopetz, Christopher Garrett, Steven A Curley, Eddie K Abdalla.   

Abstract

BACKGROUND: An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined. STUDY
DESIGN: Data on 156 consecutive patients with synchronous resectable CLM and intact primary were reviewed. Surgical strategies were defined as combined (combined resection of primary and liver), classic (primary before liver), and reverse (liver before primary) after preoperative chemotherapy. Postoperative morbidity and mortality rates and overall survival were analyzed.
RESULTS: One hundred forty-two patients (83%) had resection of all disease. Seventy-two patients underwent classic, 43 combined, and 27 reverse strategies. Median numbers of CLMs per patient were 1 in the combined, 3 in the classic, and 4 in the reverse strategy group (p = 0.01 classic vs reverse; p < 0.001 reverse vs combined). Postoperative mortality rates in the combined, classic, and reverse strategies were 5%, 3%, and 0%, respectively (p = NS), and postoperative cumulative morbidity rates were 47%, 51%, and 31%, respectively (p = NS). Three-year and 5-year overall survival rates were, respectively, 65% and 55% in the combined, 58% and 48% in the classic, and 79% and 39% in the reverse strategy (NS). On multivariate analysis, liver tumor size >3 cm (hazard ratio [HR] 2.72, 95% CI 1.52 to 4.88) and cumulative postoperative morbidity (HR 1.8, 95% CI 1.03 to 3.19) were independently associated with overall survival after surgery.
CONCLUSIONS: The classic, combined, or reverse surgical strategies in patients with synchronous presentation of CLM are associated with similar outcomes. The reverse strategy can be considered as an alternative option in patients with advanced CLM and an asymptomatic primary. Copyright (c) 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20510802     DOI: 10.1016/j.jamcollsurg.2010.02.039

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  78 in total

1.  Recent advances in the curative treatment of colorectal liver metastases.

Authors:  Andreas Andreou; Thomas A Aloia; Antoine Brouquet; Jean-Nicolas Vauthey
Journal:  Gastrointest Cancer Res       Date:  2011-07

2.  DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.

Authors:  Nicole de Rosa; Miguel A Rodriguez-Bigas; George J Chang; Jula Veerapong; Ester Borras; Sunil Krishnan; Brian Bednarski; Craig A Messick; John M Skibber; Barry W Feig; Patrick M Lynch; Eduardo Vilar; Y Nancy You
Journal:  J Clin Oncol       Date:  2016-07-18       Impact factor: 44.544

3.  Feasibility of the liver-first approach for patients with initially unresectable and not optimally resectable synchronous colorectal liver metastases.

Authors:  Masayuki Okuno; Etsuro Hatano; Yosuke Kasai; Takahiro Nishio; Satoru Seo; Kojiro Taura; Kentaro Yasuchika; Takashi Nitta; Akira Mori; Hideaki Okajima; Toshimi Kaido; Suguru Hasegawa; Shigemi Matsumoto; Yoshiharu Sakai; Shinji Uemoto
Journal:  Surg Today       Date:  2015-08-28       Impact factor: 2.549

4.  Laparoscopic simultaneous resection of colorectal primary tumor and liver metastases: a propensity score matching analysis.

Authors:  Hadrien Tranchart; David Fuks; Luca Vigano; Stefano Ferretti; François Paye; Go Wakabayashi; Alessandro Ferrero; Brice Gayet; Ibrahim Dagher
Journal:  Surg Endosc       Date:  2015-08-15       Impact factor: 4.584

5.  Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients.

Authors:  Ching-Wei D Tzeng; Amanda B Cooper; Jean-Nicolas Vauthey; Steven A Curley; Thomas A Aloia
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

6.  Patients with multiple synchronous colonic cancer hepatic metastases benefit from enrolment in a "liver first" approach protocol.

Authors:  Dimitrios Kardassis; Achilleas Ntinas; Dimosthenis Miliaras; Alexandros Kofokotsios; Konstantinos Papazisis; Dionisios Vrochides
Journal:  World J Hepatol       Date:  2014-07-27

7.  Simultaneous resection for colorectal cancer and synchronous liver metastases.

Authors:  Yasuyuki Fukami; Yuji Kaneoka; Atsuyuki Maeda; Yuichi Takayama; Shunsuke Onoe; Masatoshi Isogai
Journal:  Surg Today       Date:  2015-05-26       Impact factor: 2.549

8.  Management of colorectal liver metastases: past, present, and future.

Authors:  Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Updates Surg       Date:  2011-03

9.  Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis.

Authors:  Skye C Mayo; Carlo Pulitano; Hugo Marques; Jorge Lamelas; Christopher L Wolfgang; Wassila de Saussure; Michael A Choti; Isabelle Gindrat; Luca Aldrighetti; Eduardo Barrosso; Gilles Mentha; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-02-21       Impact factor: 6.113

10.  Biofunctionalized Hybrid Magnetic Gold Nanoparticles as Catalysts for Photothermal Ablation of Colorectal Liver Metastases.

Authors:  Sarah B White; Dong-Hyun Kim; Yang Guo; Weiguo Li; Yihe Yang; Jeane Chen; Venkateswara R Gogineni; Andrew C Larson
Journal:  Radiology       Date:  2017-07-13       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.